Key Summary
- MHRA and HRA launched clinical trial reforms.
- Setup times dropped from 169 to 122 days for commercial trials, exceeding the government's 150-day target.
- Reforms push overseas safety data and computer simulations while maintaining safety standards.
The MHRA and HRA have launched the UK's biggest clinical trial reforms in over 20 years on 28 April, which would enable faster patient access to innovative treatments.
Key changes include notifiable trials - a fast-track for lower-risk studies - and Route B substantial modifications, automatically approved unless safety concerns arise within 14 days.
The setup times have already dropped from 169 to 122 days for commercial trials, exceeding the government's 150-day target. Combined MHRA/HRA safety-ethics reviews now average 41 days - less than half the time it took a few years ago.
The pilot Route B processed modifications in just seven days, with over half from commercial sponsors.
Reforms simplify low-risk studies, embrace overseas safety data meeting UK standards, and use computer simulations to predict drug behavior pre-patient testing.
Trial registration and summary results publication become legally mandatory for the first time, boosting transparency.
Health minister Dr. Zubir Ahmed said: “This is a landmark moment for patients, researchers, and our thriving life sciences sector that will make a real, tangible difference for thousands of people waiting for new treatments. The government set itself an ambitious target to cut clinical trial set-up times to 150 days - and I am proud to say we’ve gone further and faster than that.”
MHRA chief executive Lawrence Tallon added: “These reforms to clinical trial regulations are a boost both for patients and industry investment in R&D in this country. We have listened carefully to the needs of patients, clinicians, researchers and industry to ensure we are delivering the most efficient, streamlined approvals process without compromising safety.”
HRA Chief Executive Matt Westmore noted: “The updated regulations will bring greater transparency, faster approvals for clinical trials and simpler approaches for low-risk trials - making it quicker and easier to set up and run trials while placing patients at the centre of medical research.”
The MHRA Clinical Trials Hub offers guidance and webinars shaped by stakeholder feedback. Patients and researchers benefit from quicker setups; industry gains a competitive UK destination. Safety remains paramount throughout streamlined approvals.
